GlassScriptPhysician profile
Deborah L Duncan
NPI 1760452247
$10,198.30
in general payments reported to CMS, 2019-2025
54 companies · $1,873 in 2025
The $1,873 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,948 · 2020: $615 · 2021: $672 · 2022: $1,893 · 2023: $1,715 · 2024: $1,482 · 2025: $1,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,914 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,913.72 |
| Education | $155.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,358.26 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,183.82 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $1,115.64 | 2019-2025 | |
| Abbvie INC. | $863.42 | 2021-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $498.74 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $454.88 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $427.40 | 2019-2025 | Veozah |
| Amgen INC. | $373.03 | 2019-2025 | Evenity, Prolia |
| Radius Health, INC. | $266.56 | 2019-2025 | Tymlos |
| Biohaven Pharmaceutical Holding Company LTD. | $262.47 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $261.16 | 2022-2025 | Rexulti |
| Nevro Corp. | $249.98 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $243.21 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $214.87 | 2022-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $207.31 | 2020-2023 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.